(0.27%) 5 113.66 points
(0.29%) 38 352 points
(0.28%) 15 973 points
(-0.93%) $83.07
(5.56%) $2.03
(0.37%) $2 356.00
(0.41%) $27.65
(3.98%) $958.80
(-0.21%) $0.933
(-0.37%) $10.98
(-0.53%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer...
Stats | |
---|---|
本日の出来高 | 19.39M |
平均出来高 | 1.63M |
時価総額 | 43.15B |
EPS | $0 ( 2024-04-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -57.19 |
ATR14 | $1.424 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-14 | Baker Bros. Advisors Lp | Sell | 42 977 301 | Common Stock |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 8 750 | Stock Options (right to buy) |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
2023-12-14 | Baker Bros. Advisors Lp | Sell | 9 260 | Stock Options (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 44 783 214 |
ボリューム 相関
Seattle Genetics Inc 相関
10 最も負の相関 | |
---|---|
ESSA | -0.937 |
BSRR | -0.937 |
FNCB | -0.936 |
SIRI | -0.934 |
APEI | -0.921 |
BRKL | -0.92 |
BLFY | -0.919 |
ONEM | -0.916 |
FLIC | -0.913 |
BCOW | -0.912 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Seattle Genetics Inc 相関 - 通貨/商品
Seattle Genetics Inc 財務諸表
Annual | 2022 |
収益: | $1.96B |
総利益: | $1.55B (79.10 %) |
EPS: | $-3.30 |
FY | 2022 |
収益: | $1.96B |
総利益: | $1.55B (79.10 %) |
EPS: | $-3.30 |
FY | 2021 |
収益: | $1.57B |
総利益: | $1.26B (80.21 %) |
EPS: | $-3.70 |
FY | 2020 |
収益: | $2.18B |
総利益: | $1.96B (89.99 %) |
EPS: | $3.51 |
Financial Reports:
No articles found.
Seattle Genetics Inc
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。